These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 33913760)

  • 1. Tenofovir Alafenamide for HIV Prevention: Review of the Proceedings from the Gates Foundation Long-Acting TAF Product Development Meeting.
    Romano JW; Baum MM; Demkovich ZR; Diana F; Dobard C; Feldman PL; Garcia-Lerma JG; Grattoni A; Gunawardana M; Ho DK; Hope TJ; Massud I; Milad M; Moss JA; Pons-Faudoa FP; Roller S; van der Straten A; Srinivasan S; Veazey RS; Zane D
    AIDS Res Hum Retroviruses; 2021 Jun; 37(6):409-420. PubMed ID: 33913760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Why Are Patients Switching from Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) to Tenofovir Alafenamide/Emtricitabine (Descovy) for Pre-Exposure Prophylaxis?
    D'Angelo AB; Westmoreland DA; Carneiro PB; Johnson J; Grov C
    AIDS Patient Care STDS; 2021 Aug; 35(8):327-334. PubMed ID: 34375141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Concept Evaluation Study of a New Combination Bictegravir plus Tenofovir Alafenamide Nanoformulation with Prolonged Sustained-Drug-Release Potency for HIV-1 Preexposure Prophylaxis.
    Mandal S; Prathipati PK; Sunagawa SW; Destache CJ
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33526487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis.
    Neilan AM; Landovitz RJ; Le MH; Grinsztejn B; Freedberg KA; McCauley M; Wattananimitgul N; Cohen MS; Ciaranello AL; Clement ME; Reddy KP; Hyle EP; Paltiel AD; Walensky RP
    Ann Intern Med; 2022 Apr; 175(4):479-489. PubMed ID: 35099992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission.
    Mandal S; Kang G; Prathipati PK; Zhou Y; Fan W; Li Q; Destache CJ
    J Control Release; 2019 Jan; 294():216-225. PubMed ID: 30576746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling.
    Rajoli RKR; Demkovich ZR; Flexner C; Owen A; Siccardi M
    Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32423957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 28-Day Toxicity Study of Tenofovir Alafenamide Hemifumarate by Subcutaneous Infusion in Rats and Dogs.
    Zane D; Roller S; Shelton J; Singh R; Jain R; Wang Y; Yang B; Felx M; Alessi T; Feldman PL
    Microbiol Spectr; 2021 Sep; 9(1):e0033921. PubMed ID: 34190595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis.
    Gunawardana M; Remedios-Chan M; Miller CS; Fanter R; Yang F; Marzinke MA; Hendrix CW; Beliveau M; Moss JA; Smith TJ; Baum MM
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3913-9. PubMed ID: 25896688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trans-urocanic acid enhances tenofovir alafenamide stability for long-acting HIV applications.
    Sizovs A; Pons-Faudoa FP; Malgir G; Shelton KA; Bushman LR; Chua CYX; Anderson PL; Nehete PN; Sastry KJ; Grattoni A
    Int J Pharm; 2020 Sep; 587():119623. PubMed ID: 32663582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial.
    Nair G; Celum C; Szydlo D; Brown ER; Akello CA; Nakalega R; Macdonald P; Milan G; Palanee-Phillips T; Reddy K; Tahuringana E; Muhlanga F; Nakabiito C; Bekker LG; Siziba B; Hillier SL; Baeten JM; Garcia M; Johnson S; McClure T; Levy L; Livant E; Jacobson C; Soto-Torres L; van der Straten A; Hosek S; Rooney JF; Steytler J; Bunge K; Parikh U; Hendrix C; Anderson P; Ngure K;
    Lancet HIV; 2023 Dec; 10(12):e779-e789. PubMed ID: 37898146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis.
    Jamieson L; Johnson LF; Nichols BE; Delany-Moretlwe S; Hosseinipour MC; Russell C; Meyer-Rath G
    Lancet HIV; 2022 Dec; 9(12):e857-e867. PubMed ID: 36356603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis.
    Walensky RP; Horn T; McCann NC; Freedberg KA; Paltiel AD
    Ann Intern Med; 2020 May; 172(9):583-590. PubMed ID: 32150602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-Focused Selection of PrEP Medication for Individuals at Risk of HIV: A Narrative Review.
    Fields SD; Tung E
    Infect Dis Ther; 2021 Mar; 10(1):165-186. PubMed ID: 33569743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial.
    Landovitz RJ; Hanscom BS; Clement ME; Tran HV; Kallas EG; Magnus M; Sued O; Sanchez J; Scott H; Eron JJ; Del Rio C; Fields SD; Marzinke MA; Eshleman SH; Donnell D; Spinelli MA; Kofron RM; Berman R; Piwowar-Manning EM; Richardson PA; Sullivan PA; Lucas JP; Anderson PL; Hendrix CW; Adeyeye A; Rooney JF; Rinehart AR; Cohen MS; McCauley M; Grinsztejn B;
    Lancet HIV; 2023 Dec; 10(12):e767-e778. PubMed ID: 37952550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalizing prevention: Advances in pharmacotherapy for HIV prevention.
    Brizzi M; Sherman EM; Green SB; Nowicki DN; Drwiega EN; Nicol MR; Chastain DB; Sahloff EG; Truong WR; Cluck D; Badowski ME; Michienzi SM; Durham SH
    Pharmacotherapy; 2023 Apr; 43(4):305-320. PubMed ID: 36938645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical Considerations for Long-acting Delivery of Tenofovir Alafenamide from Subdermal Implants for HIV Pre-exposure Prophylaxis.
    Gunawardana M; Remedios-Chan M; Sanchez D; Fanter R; Webster S; Webster P; Moss JA; Trinh M; Beliveau M; Ramirez CM; Marzinke MA; Kuo J; Gallay PA; Baum MM
    Pharm Res; 2023 Jul; 40(7):1657-1672. PubMed ID: 36418671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single dose topical inserts containing tenofovir alafenamide fumarate and elvitegravir provide pre- and post-exposure protection against vaginal SHIV infection in macaques.
    Dobard CW; Peet MM; Nishiura K; Holder A; Dinh C; Mitchell J; Khalil G; Pan Y; Singh ON; McCormick TJ; Agrahari V; Gupta P; Jonnalagadda S; Heneine W; Clark MR; García-Lerma JG; Doncel GF
    EBioMedicine; 2022 Dec; 86():104361. PubMed ID: 36423375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preexposure Prophylaxis for the Prevention of HIV: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Chou R; Spencer H; Bougatsos C; Blazina I; Ahmed A; Selph S
    JAMA; 2023 Aug; 330(8):746-763. PubMed ID: 37606667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fundamental aspects of long-acting tenofovir alafenamide delivery from subdermal implants for HIV prophylaxis.
    Gunawardana M; Remedios-Chan M; Sanchez D; Webster S; Castonguay AE; Webster P; Buser C; Moss JA; Trinh M; Beliveau M; Hendrix CW; Marzinke MA; Tuck M; Caprioli RM; Reyzer ML; Kuo J; Gallay PA; Baum MM
    Sci Rep; 2022 May; 12(1):8224. PubMed ID: 35581262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic delivery of bictegravir and tenofovir alafenamide using dissolving microneedles for HIV preexposure prophylaxis.
    Zhang C; Wu Y; Hutton ARJ; Hidayat Bin Sabri A; Hobson JJ; Savage AC; McCarthy HO; Paredes AJ; Owen A; Rannard SP; Donnelly RF
    Int J Pharm; 2024 Jul; 660():124317. PubMed ID: 38851410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.